What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc. is a Nasdaq Capital Market-listed, clinical-stage biopharmaceutical company trading under CYCN. It was separated from Ironwood Pharmaceuticals in April 2019 to hold and develop a portfolio of soluble guanylate cyclase, or sGC, stimulators. The company has since changed direction repeatedly: it sold most internally developed CNS assets, retained economic interests in several legacy programs, and began building a new treatment-resistant depression program. Cyclerion has also agreed to merge with privately held Korsana Biosciences, potentially turning CYCN into the listing vehicle for an Alzheimer’s-focused pipeline.
A very small operating company with several economic claims
Cyclerion is not a commercial pharmaceutical manufacturer and does not have recurring product sales. Its legacy portfolio includes praliciguat, licensed to Akebia Therapeutics; zagociguat and CY3018, sold to Tisento Therapeutics; and olinciguat, which Cyclerion continues to seek to out-license. Its newer pre-merger program, CYC-126, combines established pharmacology with enabling delivery and physiological-monitoring technology for individualized treatment of treatment-resistant depression. The company’s official asset overview is a mix of retained rights, milestones, royalties and one internally planned program rather than a conventional funded pipeline.
Why the company matters despite its size
Cyclerion illustrates how a micro-cap biotech can evolve from drug developer into an asset-monetization and transaction platform. Its value is driven less by near-term sales than by externally controlled clinical events, the $5.35 million Tisento investment, possible Akebia payments and the proposed Korsana merger. CYCN therefore resembles a portfolio of contingent claims more than a mature operating business.
How does Cyclerion make money?
Cyclerion’s revenue is episodic. It recognizes cash or accounting revenue when a licensee pays an upfront fee, an option is extended, development materials are purchased, a clinical milestone is achieved, or a future commercial royalty becomes payable. The model can produce attractive economics, but timing depends on counterparties, trials, regulation and contract accounting.
Which assets create the economic upside?
| Asset or agreement | Current role | Economic mechanism | Key disclosed fact |
|---|---|---|---|
| Praliciguat / Akebia | Phase 2 FSGS program controlled by Akebia | Development, regulatory and commercial milestones plus royalties | $1.0M milestone received in February 2026; up to $557.5M of additional potential milestones; royalties from mid-single digits to 20% |
| Tisento equity interest | Minority investment tied to zagociguat and CY3018 | Possible equity appreciation or liquidity event | $5.35M carrying value at March 31, 2026; Cyclerion lacks operational control |
| Olinciguat | Phase 2 vascular sGC asset seeking a new licensee | Potential upfront, milestone and royalty economics | Prior option terminated in October 2025 after negotiations failed |
| CYC-126 | Pre-merger individualized TRD development program | Future proprietary product economics, subject to financing and development | MIT and Medsteer obligations include potential milestones and low-single-digit royalties |
Why revenue quality matters more than revenue growth
FY2025 revenue rose 3.7% from $2.000 million in FY2024, but composition changed substantially. The $0.8 million purchase-agreement payment and $0.274 million option revenue were discrete events. Q1 2026 then produced no revenue, confirming that a simple growth multiple would misrepresent the business. A better framework separates received cash from probability-weighted milestones and treats royalties as long-duration options. The 2025 Form 10-K provides the most complete description of these agreements and their accounting treatment.
Which turning points shaped Cyclerion’s strategy?
Cyclerion’s history is a sequence of efforts to preserve scientific value while shifting development cost to partners. That reduced spending, but also reduced control and increased dependence on contingent payments.
-
2019Ironwood completed the tax-free spin-off of its sGC business. Cyclerion began as an independent, research-intensive biotechnology company with multiple internally controlled programs.
-
2021Praliciguat was licensed globally to Akebia. The agreement transferred future development spending to Akebia and converted the asset into milestone and royalty exposure.
-
2023Cyclerion sold zagociguat and CY3018 to Tisento and received a minority equity interest. This sharply reduced direct CNS development activity while preserving indirect exposure.
-
2024The company entered an option arrangement for olinciguat and later amended the Akebia agreement, showing a strategy centered on harvesting legacy assets rather than rebuilding the old pipeline.
-
2025Cyclerion licensed MIT intellectual property and prioritized CYC-126 for treatment-resistant depression. R&D expense rose to $0.959 million as the company restarted development planning.
-
January 2026A Medsteer collaboration added delivery and physiological-monitoring capabilities intended to support individualized administration of CYC-126.
-
April–July 2026Cyclerion signed the Korsana merger agreement and continued filing transaction materials. The story shifted toward a proposed Alzheimer’s-focused combined company.
The reset creates two analytical periods: a one-employee Cyclerion managing CYC-126 and legacy economics, and a potential post-merger holder of a small interest in Korsana’s funded Alzheimer’s platform. Forecasts should keep them separate.
What does Cyclerion’s latest quarter show?
The quarter ended March 31, 2026 shows a company spending ahead of a strategic transaction while generating no operating revenue. The latest Form 10-Q reported higher research, legal and consulting activity, lower cash, increased current liabilities and another equity issuance.
Latest reported financial snapshot
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.000M | $0.081M | No recurring operating base; prior-period revenue came from an option extension and reimbursement |
| R&D expense | $0.730M | $0.036M | A 1,928% increase, reflecting CYC-126 development and licensing activity |
| G&A expense | $2.479M | $1.502M | A 65% increase; corporate, legal and transaction costs dominate the cost base |
| Operating loss | $(3.209)M | $(1.457)M | Loss expanded 120% while revenue fell to zero |
| Net loss per share | $(0.76) | $(0.56) | Weighted-average common shares rose from 2.556M to 4.205M |
| Cash at period end | $2.823M | $3.639M | Liquidity remained limited despite $0.825M of Q1 2026 ATM proceeds |
Why the expense mix is a warning signal
Merger preparation, legal work and public-company reporting explain part of the high corporate-cost ratio, but the standalone model still has limited operating leverage. Without a transaction, milestone receipt or new capital, administrative costs can deplete cash even before a full clinical program is funded.
How financially strong is Cyclerion?
Cyclerion has no reported debt in its latest balance sheet, but “debt-free” should not be confused with financially strong. Its principal constraint is short cash runway relative to development and public-company obligations. At March 31, 2026, current assets were $3.089 million and current liabilities were $1.714 million, producing a current ratio of roughly 1.8 times, down from about 5.2 times at December 31, 2025. Stockholders’ equity declined 25.3% during the quarter to $6.791 million.
| Financial measure | March 31, 2026 | December 31, 2025 | What changed |
|---|---|---|---|
| Cash and cash equivalents | $2.823M | $3.240M | Down 12.9% after operating and equipment cash use exceeded ATM proceeds |
| Current assets | $3.089M | $4.635M | Accounts receivable fell by $1.0M after collection |
| Other investment | $5.350M | $5.350M | Tisento carrying value was unchanged but remains illiquid and outside Cyclerion’s control |
| Current liabilities | $1.714M | $0.900M | Up 90.4%, mainly from accrued expenses and other current liabilities |
| Stockholders’ equity | $6.791M | $9.085M | Quarterly loss more than offset equity issuance and share-based compensation |
| Accumulated deficit | $(274.197)M | $(271.020)M | Reflects the cumulative cost of years of research and restructuring |
Cash flow and financing dependence
FY2025 operating cash use was $3.314 million, improved from $4.333 million in FY2024. Financing supplied $3.322 million, including $2.077 million from the at-the-market program and $1.375 million from a private placement before $0.130 million of issuance costs. In Q1 2026, another 405,000 common shares generated $0.825 million. Equity issuance, not internal cash flow, has funded the runway.
Why is the Korsana merger the dominant strategic event?
Cyclerion and Korsana announced an all-stock merger on April 1, 2026. A July 2026 filing still described closing as expected in Q3 2026. The combined company plans to use the Korsana name and KRSA ticker, with Cyclerion contributing its listing and negotiated net-cash position.
What business would legacy holders actually own?
KRSA-028 is a shuttled monoclonal antibody targeting amyloid beta. Korsana’s THETA platform uses transferrin-receptor and Fc engineering to improve brain delivery. The objective is strong plaque clearance with lower safety burden and low-volume subcutaneous administration. The official merger announcement projected Phase 1 healthy-volunteer data in mid-2027 and interim proof-of-concept amyloid-plaque data by the end of 2027.
The merger converts the valuation problem
Before closing, valuation centers on Cyclerion net cash, legacy assets and transaction probability. After closing, KRSA-028, burn rate, clinical timing and dilution dominate. The July 10, 2026 Korsana presentation filed with the SEC is therefore more relevant to the post-merger story than historical CYCN revenue.
What gives Cyclerion competitive leverage, and who are the competitors?
Cyclerion’s standalone competitive position is weak in conventional scale terms. It has one employee, limited cash and no commercial infrastructure. Its leverage comes from contractual rights, accumulated scientific work, specialist relationships and a public listing capable of supporting strategic transactions. For CYC-126, the proposed differentiation is individualized administration that combines approved anesthetic pharmacology with controlled delivery and physiological monitoring. That concept must still demonstrate safety, efficacy and a practical regulatory path.
| Competitive reference | Area | Cyclerion or Korsana differentiation | Main pressure |
|---|---|---|---|
| Janssen / Spravato | Approved TRD pharmacotherapy | CYC-126 aims for individualized delivery and monitoring rather than a standard fixed regimen | Spravato already has regulatory approval, physician familiarity and commercial infrastructure |
| Eli Lilly / Symbyax | Approved TRD pharmacotherapy | Potentially different mechanism and treatment setting | Established evidence, brand and payer pathways |
| Compass Pathways and Axsome | Novel or rapid-acting depression therapies | Technology-enabled precision and reproducibility are the intended CYC-126 advantages | Better-funded development programs and competing trial recruitment |
| Roche / trontinemab | Shuttled anti-amyloid antibody | KRSA-028 is designed for improved half-life, lower-volume subcutaneous dosing and reduced safety burden | Roche has human data, greater resources and a more advanced program |
| Lilly / donanemab and remternetug | Plaque-selective anti-amyloid therapy | KRSA-028 combines the pyroglutamate target with a brain shuttle and engineered Fc profile | Approved or Phase 3 products set demanding efficacy, safety and convenience benchmarks |
Is there a durable moat?
These are analytical summaries, not investment grades. The potential moat is primarily intellectual property and differentiated clinical performance. Until human data confirms that differentiation, the resource-based advantage is prospective rather than established.
Who owns Cyclerion stock, and why does governance matter?
Cyclerion has one class of publicly traded common stock and 351,037 shares of Series A convertible preferred stock. Ownership is unusually concentrated around director and former chief executive Peter Hecht. The company’s amended 2025 annual filing reports beneficial ownership using 4,330,314 common shares outstanding plus the preferred shares convertible into common stock. Because the proposed merger requires shareholder approval, insider concentration and support agreements materially affect transaction certainty.
| Holder or group | Beneficial shares | Beneficial ownership | Governance implication |
|---|---|---|---|
| Peter M. Hecht, Ph.D. | 1,021,224 | 21.3% | Largest disclosed insider position; includes preferred conversion and aligns him closely with transaction value |
| Regina M. Graul, Ph.D. | 124,423 | 2.6% | CEO incentives include equity and a potential transaction bonus of up to $150,000 |
| Errol B. De Souza, Ph.D. | 52,500 | 1.1% | Board chair with restricted-stock and option exposure |
| All directors and executive officers | 1,286,258 | 26.6% | Collective insider ownership is large enough to influence strategic votes |
| Merger support group | Not presented on the same beneficial-ownership basis | About 24.2% of capital as converted at March 31, 2026 | Directors and officers agreed to support the merger and reverse stock split |
Board structure and transaction incentives
The 2025 Form 10-K amendment also indicates that outstanding unvested options accelerate at the merger and that directors and officers entered support agreements. These provisions make incentive analysis essential. Legacy shareholders should assess both the strategic rationale and insiders’ closing economics.
Which assets and KPIs matter most?
Product revenue, gross margin and market share are not yet useful. The dashboard should instead track liquidity, dilution, partner progress, clinical milestones and transaction conditions. The company’s science description explains the sGC background; economic value depends on program control and funding responsibility.
| KPI | Latest disclosed reference | How to interpret it |
|---|---|---|
| Cash runway | Cash expected to fund operations into Q3 2026 | Immediate standalone constraint; merger delay raises financing risk |
| Quarterly operating cash use | $(1.176)M in Q1 2026 | Compare with cash and equity proceeds to assess funding pressure |
| Common shares outstanding | 4.241M at March 31, 2026; 4.330M reported outstanding at May 10, 2026 | Measures dilution from ATM issuance and other equity actions |
| Akebia clinical progress | Praliciguat Phase 2 FSGS study initiated; $1.0M milestone paid in February 2026 | Future milestones and royalties depend on externally controlled development success |
| Tisento PRIZM data | About 43 participants enrolled; top-line MELAS results expected Q4 2026 | Potential signal for the illiquid Tisento investment |
| Merger ownership exchange | About 1.5% for pre-merger Cyclerion holders at announcement | Net-cash adjustments or financing terms can materially affect legacy economics |
| KRSA-028 clinical milestones | Healthy-volunteer data targeted for mid-2027; interim plaque-clearance data by end-2027 | Central post-merger value checkpoints |
A practical monitoring dashboard
What opportunities and risks could change the story?
Cyclerion’s opportunities are paired with binary or financing risk. External capital and partner-controlled science could create value without Cyclerion funding every stage, but short runway and transaction dependence leave little room for delay.
| Driver | Opportunity | Risk or constraint | Financial line affected |
|---|---|---|---|
| Korsana merger | Adds a funded neurodegeneration platform and approximately $380M of gross financing | Closing conditions, dilution to about 1.5%, integration and future clinical failure | Ownership percentage, cash, R&D expense and future share count |
| KRSA-028 | Potentially differentiated brain delivery, safety and subcutaneous convenience | Preclinical promise may not translate into human efficacy or tolerability | Post-merger R&D, milestone timing and enterprise value |
| Akebia praliciguat | Up to $557.5M of additional stated milestones and tiered royalties | Most milestone value is uncertain, long dated and controlled by Akebia | License revenue, cash and contingent value |
| Tisento stake | Positive PRIZM data or a financing event could increase value | Illiquidity, dilution, lack of control and possible full loss of investment | Other investment and potential impairment |
| CYC-126 | Addresses a large unmet TRD need with an individualized approach | Rights, funding, regulatory pathway and strategic priority may change after merger | R&D, license obligations and future capital needs |
| Nasdaq listing | Provides access to public equity and transaction currency | Listing compliance and reverse-split requirements can pressure liquidity and ownership | Financing capacity and share structure |
The risks are interconnected
The filings also identify intellectual-property, regulatory, reimbursement, third-party and internal-control risks. These interact: a clinical delay can trigger financing, financing increases dilution, and dilution changes merger economics.
What is the key takeaway from Cyclerion Therapeutics analysis?
Cyclerion is not a conventional revenue-growth company. FY2025 revenue of $2.074 million came from discrete agreements, while Q1 2026 revenue was zero. With $2.823 million of cash at March 31, 2026 and runway estimated only into Q3 2026, financing and transaction execution dominate the analysis.
How should a DCF or valuation model handle CYCN?
A smooth DCF is inappropriate; scenario analysis is better. The standalone case values net cash, Tisento, probability-weighted Akebia economics, possible olinciguat licensing and public-company costs. The merger case values the legacy percentage in Korsana, then models financing, burn, KRSA-028 probabilities and dilution. A failed-transaction case includes emergency financing and possible asset impairment.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.